Expanding the Arsenal of Clinically Active KRAS G12C Inhibitors.

doi:10.1200/JCO.22.00562

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Expanding the Arsenal of Clinically Active KRAS G12C Inhibitors.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 10 Aug 2022

Arbour Kathryn C, Lito Piro

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Line, Tumor
Share to Lung Neoplasms
Share to Mutation
Share to Proto-Oncogene Proteins p21(ras)

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Open in PubMed

Identifiers

PMID: 35763705
DOI: 10.1200/JCO.22.00562

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Expanding the Arsenal of Clinically Active KRAS G12C Inhibitors.PMID 35763705Read ↗

A bright future for KRAS inhibitors.Semantic proximity Read ↗

Expanding the options for KRAS inhibition.Semantic proximity Read ↗

Multiple initiatives to conquer KRAS G12C inhibitor resistance from the perspective of clinical therapy.Semantic proximity Read ↗

The Research Progress of Direct KRAS G12C Mutation Inhibitors.Semantic proximity Read ↗

The KRASG12D Inhibitor Pipeline Grows.Semantic proximity Read ↗

Emerging landscape of KRAS inhibitors in cancer treatment.Semantic proximity Read ↗

Targeting mutant KRAS.Semantic proximity Read ↗

Targeting KRAS with reversible inhibitors.Semantic proximity Read ↗

KRAS-G12C covalent inhibitors: A game changer in the scene of cancer therapies.Semantic proximity Read ↗

Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants.Semantic proximity Read ↗

Next batter up! Targeting cancers with KRAS-G12D mutations.Semantic proximity Read ↗

Unlocking KRAS: Navigating Its Molecular Biology and Treatment Landscape Among Gastrointestinal Malignancies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.